|
1.
|
Parkin DM, Whelan SL, Ferlay J, Raymond L
and Young J: Cancer Incidence in Five Continents. IARC Scientific
Publications. 143:814–815. 1997.
|
|
2.
|
Xiao WW, Huang SM, Han F, et al: Local
control, survival, and late toxicities of locally advanced
nasopharyngeal carcinoma treated by simultaneous modulated
accelerated radiotherapy combined with cisplatin concurrent
chemotherapy: long-term results of a phase 2 study. Cancer.
117:1874–1883. 2011. View Article : Google Scholar
|
|
3.
|
Ng WT, Lee MC, Hung WM, et al: Clinical
outcomes and patterns of failure after intensity-modulated
radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol
Phys. 79:420–428. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Song CH, Wu HG, Heo DS, Kim KH, Sung MW
and Park CI: Treatment outcomes for radiotherapy alone are
comparable with neoadjuvant chemotherapy followed by radiotherapy
in early-stage nasopharyngeal carcinoma. Laryngoscope. 118:663–670.
2008. View Article : Google Scholar
|
|
5.
|
Lee AW, Lau WH, Tung SY, Chua DT, Chappell
R, et al: Preliminary results of a randomized study on therapeutic
gain by concurrent chemotherapy for regionally-advanced
nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong
Nasopharyngeal Cancer Study Group. J Clin Oncol. 23:6966–6975.
2005. View Article : Google Scholar
|
|
6.
|
Wee J, Tan EH, Tai BC, et al: Randomized
trial of radiotherapy versus concurrent chemoradiotherapy followed
by adjuvant chemotherapy in patients with American Joint Committee
on Cancer/International Union against cancer stage III and IV
nasopharyngeal cancer of the endemic variety. J Clin Oncol.
23:6730–6738. 2005. View Article : Google Scholar
|
|
7.
|
Herbst RS and Langer CJ: Epidermal growth
factor receptors as a target for cancer treatment: the emerging
role of IMC-C225 in the treatment of lung and head and neck
cancers. Semin Oncol. 29(Suppl 4): S27–S36. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Meche A, Cimpean AM and Raica M:
Immunohistochemical expression and significance of epidermal growth
factor receptor (EGFR) in breast cancer. Rom J Morphol Embryol.
50:217–221. 2009.PubMed/NCBI
|
|
9.
|
Hirsch FR, Varella-Garcia M and Cappuzzo
F: Predictive value of EGFR and HER2 overexpression in advanced
non-small-cell lung cancer. Oncogene. 28(Suppl 1): S32–S37. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Leong JL, Loh KS, Putti TC, Goh BC and Tan
LK: Epidermal growth factor receptor in undifferentiated carcinoma
of the nasopharynx. Laryngoscope. 114:153–157. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Yuan TZ, Li XX, Cao Y, Qian CN, Zeng MS
and Guo X: Correlation of epidermal growth factor receptor
activation to metastasis-free survival of nasopharyngeal carcinoma
patients. Ai Zheng. 27:449–454. 2008.(In Chinese).
|
|
12.
|
Yuan Y, Zhou X, Song J, et al: Expression
and clinical significance of epidermal growth factor receptor and
type 1 insulin-like growth factor receptor in nasopharyngeal
carcinoma. Ann Otol Rhinol Laryngol. 117:192–200. 2008.PubMed/NCBI
|
|
13.
|
Moyer JD, Barbacci EG, Iwata KK, et al:
Induction of apoptosis and cell cycle arrest by CP-358,774, an
inhibitor of epidermal growth factor receptor tyrosine kinase.
Cancer Res. 57:4838–4848. 1997.PubMed/NCBI
|
|
14.
|
Pollack VA, Savage DM, Baker DA, et al:
Inhibition of epidermal growth factor receptor-associated tyrosine
phosphorylation in human carcinomas with CP-358,774: dynamics of
receptor inhibition in situ and antitumor effects in athymic mice.
J Pharmacol Exp Ther. 291:739–748. 1999.
|
|
15.
|
Ng SS, Tsao MS, Nicklee T and Hedley DW:
Effects of the epidermal growth factor receptor inhibitor OSI-774,
Tarceva, on downstream signaling pathways and apoptosis in human
pancreatic adenocarcinoma. Mol Cancer Ther. 1:777–783.
2002.PubMed/NCBI
|
|
16.
|
Chinnaiyan P, Huang S, Vallabhaneni G, et
al: Mechanisms of enhanced radiation response following epidermal
growth factor receptor signaling inhibition by erlotinib (Tarceva).
Cancer Res. 65:3328–3335. 2005.
|
|
17.
|
Ma BB, Poon TC, To KF, et al: Prognostic
significance of tumor angiogenesis, Ki 67, p53 oncoprotein,
epidermal growth factor receptor and HER2 receptor protein
expression in undifferentiated nasopharyngeal carcinoma - a
prospective study. Head Neck. 25:864–872. 2003. View Article : Google Scholar
|
|
18.
|
Bonner JA, Harari PM, Giralt J, et al:
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head
and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Bonner JA, Harari PM, Giralt J, et al:
Radiotherapy plus cetuximab for locoregionally advanced head and
neck cancer: 5-year survival data from a phase 3 randomized trial,
and relation between cetuximab induced rash and survival. Lancet
Oncol. 11:21–28. 2010.PubMed/NCBI
|
|
20.
|
Nyati MK, Morgan MA, Feng FY and Lawrence
TS: Integration of EGFR inhibitors with radiochemotherapy. Nat Rev
Cancer. 6:876–885. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Tortora G, Gelardi T, Ciardiello F and
Bianco R: The rationale for the combination of selective EGFR
inhibitors with cytotoxic drugs and radiotherapy. Int J Biol
Markers. 22(Suppl 4): S47–S52. 2007.PubMed/NCBI
|
|
22.
|
Bai XX, Mou XX, Jiang SJ, et al: Effects
of Erlotinib on apoptosis in human pulmonary adenocarcinoma.
Chinese Journal of Gerontology. 30:1073–1076. 2010.(In
Chinese).
|
|
23.
|
Xiong X, Liu H, Fu L, et al: Antitumor
activity of a new N-substituted thiourea derivative, an EGFR
signaling-targeted inhibitor against a panel of human lung cancer
cell lines. Chemotherapy. 54:463–474. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Huang S, Armstrong EA, Benavente S,
Chinnaiyan P and Harari PM: Dual-agent molecular targeting of the
epidermal growth factor receptor (EGFR): combining anti-EGFR
antibody with tyrosine kinase inhibitor. Cancer Res. 64:5355–5362.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Sarkaria JN, Carlson BL, Schroeder MA, et
al: Use of an orthotopic xenograft model for assessing the effect
of epidermal growth factor receptor amplification on glioblastoma
radiation response. Clin Cancer Res. 12:2264–2271. 2006. View Article : Google Scholar : PubMed/NCBI
|
